Over $235 million has been secured for the development of BPZE1
Since licensing BPZE1 in December 2013 from the Insitut Pasteur de Lille and INSERM, ILiAD has made significant progress advancing vaccine development, including:
• Completion of a Phase 2b human challenge clinical study providing first-ever demonstration of protection against virulent B. pertussis, published in The Lancet Microbe
• Completion of a 300 subject multicenter Phase 2b clinical trial, published in The Lancet
• Completion of an NIH-sponsored Phase 2a clinical study at Vanderbilt University
• Completion of a Phase 1b clinical study at the Karolinska University Hospital in Stockholm, Sweden
• Demonstration of 99.99% reduction in B. pertussis nasopharyngeal colonization vs. controls in a non-human primate study
• Manufacturing of lyophilized vaccine formulation with > 4 years stability at 4℃, for storage and distribution
• Issuance by the U.S. and European Patent and Trademark offices of BPZE1 vaccine patents with broad claims (82 patents worldwide)
• Development and proof of concept of the B-Tech™ vector platform for the delivery of heterologous antigens for the induction of immunity against non-pertussis pathogens
ILiAD Biotechnologies, Inc. is a privately held company.